We first identified the absolute number of CD3+, CD4+, and CD8+ T cells in PB and BM in each CML group and found that there was a slightly increased trend for CD3+ T cells (1,133 cells/μl vs 2,064 cells/μl, P = 0.0883) and a significant increase in CD8+ T cells in the PB of DN-CML patients compared with HIs (368 cells/μl vs 1,581 cells/μl, P = 0.0178) (Figure 1B). This evidence concerns the gene CD4 and chronic myelogenous leukemia, BCR-ABL1 positive.